



11-2018

# Effect of Psychotropic Medication on Foster Care Experience and Outcomes: A Causal Analysis using Administrative Data

Angela Gwaltney

*University of North Carolina at Chapel Hill*

Follow this and additional works at: [https://repository.upenn.edu/admindata\\_conferences\\_presentations\\_2018](https://repository.upenn.edu/admindata_conferences_presentations_2018)

---

Gwaltney, Angela, "Effect of Psychotropic Medication on Foster Care Experience and Outcomes: A Causal Analysis using Administrative Data" (2018). *2018 ADRF Network Research Conference Presentations*. 7.  
[https://repository.upenn.edu/admindata\\_conferences\\_presentations\\_2018/7](https://repository.upenn.edu/admindata_conferences_presentations_2018/7)

**DOI** <https://doi.org/10.23889/ijpds.v3i5.1082>

This paper is posted at ScholarlyCommons. [https://repository.upenn.edu/admindata\\_conferences\\_presentations\\_2018/7](https://repository.upenn.edu/admindata_conferences_presentations_2018/7)  
For more information, please contact [repository@pobox.upenn.edu](mailto:repository@pobox.upenn.edu).

---

# Effect of Psychotropic Medication on Foster Care Experience and Outcomes: A Causal Analysis using Administrative Data

## **Abstract**

Children in foster care experienced abuse, neglect, or dependency, and for the safety and well-being of the child, must be taken out of their biological home. Not surprisingly, children in foster care have higher rates of serious emotional and behavioral problems. Although pharmacological treatments can be an important component of the treatment plan, there seems to be a higher rate of use than would be expected. An estimated 13-25% of foster children are prescribed mind- and mood-altering medication vs. 4% in the general population.

Children in foster care are considered a vulnerable population and research involving these children justifiably requires additional measures to ensure their protection. As a result, studies on the use of psychotropic medication among youth in foster care have relied primarily on secondary data, typically administrative data. This study used linked administrative datasets to rigorously examine the effect of psychotropic medication on foster care experiences and outcomes among children who entered foster care in North Carolina between March 2006 and June 2012. The dataset was constructed by linking the North Carolina's child welfare administrative records (also known as the Services Information System [SIS]) with the Medicaid claims database (also known as the Eligibility Information System [EIS]) for medical and mental health services received by the foster youth. Inverse probability of treatment weighting was calculated and applied to mimic a randomized study. Results revealed that children on medication stayed in care longer, less likely to experience placement disruption, and more likely to exit to adoption.

## **Comments**

**DOI** <https://doi.org/10.23889/ijpds.v3i5.1082>



THE UNIVERSITY  
*of* NORTH CAROLINA  
at CHAPEL HILL

## Effect of Psychotropic Medication on Foster Care Experience and Outcomes: A Causal Analysis using Administrative Data

Angela Gwaltney, MSW, PhD

ADRF CONFERENCE  
NOVEMBER 14, 2018



# Introduction

On any given day, approximately **400,540** children in foster care in the US <sup>1, 2</sup>

## Trauma Experienced

Abuse or  
Neglect

Homelessness

Exposure to  
domestic  
violence

Exposure to  
substance  
abuse

Multiple  
placements

Loss of  
Control



# Introduction

- 50-80% of children have moderate to severe mental health problems <sup>3, 4, 5</sup>
- Many prescribed psychotropic medication (reports ranging from 20% to 40%) <sup>6</sup>
- Children in foster care more likely to be prescribed psychotropic medication (2.7 to 4.5 times the rate of non-foster youth) <sup>6, 8</sup>



# What are psychotropic medications?

Psychotropic medications are medicine capable of affecting the mind, emotions, and behavior; denoting drugs used in the treatment of mental illness.



# Psychotropic medications <sup>6,7</sup>

---

## Stimulants

Treats: ADD/ADHD

*Strattera, Vyvanse, Ritalin, Concerta, Adderall, Dexedrine, Dextrostat*

Adverse effects: Decreased appetite, tics, psychosis, flat affect, difficulty sleeping

---

## Antianxiety

Treats: Generalized anxiety disorder, PTSD, social phobias

*Klonopin, Ativan, Xanax*

Adverse effects: Dependence, drowsiness and dizziness, blurred vision, nightmares, headaches

---

## Antidepressants

Treats: Depression, anxiety, OCD, social phobia

*Prozac, Celexa, Zoloft, Paxil, Lexapro, Effexor, Cymbalta, Wellbutrin*

Adverse effects: Suicidal thoughts, sleeplessness or drowsiness, agitation, sexual dysfunction, Weight gain, nausea and vomiting



# Psychotropic medications (cont.)<sup>6, 7</sup>

---

## Antipsychotics

*Thorazine, Haldol, Risperdal, Zyprexa, Seroquel, Geodon, Abilify*

Treats: bipolar disorder, schizophrenia, Tourette's syndrome

Adverse effects: rigidity, tremor, tardive dyskinesia, diabetes, high cholesterol, weight gain, neuroleptic malignant syndrome

---

## Mood stabilizers

*Lithium, Depakote, Tegretol, Lamcital, Trileptal*

Treats: Bipolar disorder, depression

Adverse effects: suicidal thoughts; loss of coordination; hallucinations; kidney, thyroid, liver and pancreatic damage; polycystic ovarian syndrome; weight gain

---

## Alpha-adrenergic agonists (AAAs)

*Clonidine, guanfacine*

Treats: ADD/ADHD, insomnia and sleep problems, PTSD

Adverse effects: Sedation, headache, excitability, restlessness

---





# Problem Statement

## Concern 1: Off-Label Use

- These medications are often “off-label”
- Off-Label:
  - Untested for efficacy and safety in pediatric populations or indication <sup>9</sup>
  - Different dosage than approved for an indication by the FDA



# Problem Statement

## Concern 2: Side Effects

Host of negative side-effects <sup>11</sup>

- Weight gain and metabolic changes
- Sedation
- Low blood pressure (Orthostatic Hypotension)
- Abnormally rapid heart rate (Tachycardia)
- Menstrual problems
- Blurred vision
- Skin rashes
- Sun sensitivity



# Problem Statement

## Concern 3: Lack of Oversight

- Children in foster care are particularly vulnerable due to lack of oversight by caretaker and agency <sup>6</sup>
- One study found that 34 of 48 states had not implemented a system to identify prescriptions with dosages exceeding current recommended maximum recommendations <sup>5</sup>



# Gap in Research

- Children in foster care are a particularly vulnerable population with high need and high rates of psychotropic medication
- Research in this area have only covered the prevalence rates of psychotropic medication thus far
- Few studies conducted beyond descriptive analysis that look at long-term causal effects of medication use
- More research is needed to understand the short- and long-term effects of foster youth receiving psychotropic medication
  - Placement types
  - Placement changes
  - Exit type
  - Health
  - Educational
  - Behavioral
  - Social



Rigorous research challenging with foster youth:  
need innovative statistical techniques to take  
advantage of existing administrative data





# Outcome Measures

Since the passage of the Adoption and Safe Families Act of 1997, the U.S. Department of Health and Human Services has established several important objectives and outcomes of interest that relate to the safety and well-being of children in foster care:

Length of  
Time in Care

Placement  
Stability

Permanency



# Research Questions

1. How does medicating children in foster care effect how long they are in care?
2. How does medicating children in foster care effect placement stability?
3. How does medicating children in foster care effect how they exit to permanency?



# Methods Overview

Data management

```
graph TD; A[Data management] --> B[Propensity score analysis (IPTW)]; B --> C[Outcome analysis];
```

Propensity score analysis (IPTW)


Outcome analysis



# Causal Analysis

## Potential Outcomes Model

*Causal effect is the difference between the potential outcome that would arise for an individual under two different treatment/exposure conditions<sup>1</sup>*



$Y_i(0)$




$Y_i(1)$

$$T_1 = Y_i(1) - Y_i(0)$$

# Criteria for Causality<sup>2</sup>



- X precedes Y
- X is related to Y
- No plausible alternative explanations for Y exist other than X





# Causal Analysis:

## Random Assignment vs. Observational Study



# Propensity Score Analysis

- PSA increasingly used to use observational studies to estimate treatment effects and outcomes <sup>3</sup>
- Reduces the effect of confounding due to differences in the distribution of measured baseline characteristics between treatment groups
- PSA mimics randomized treatment groups by comparing outcomes in treated and untreated subjects who have a similar distribution of measured baseline covariates



# Propensity Score ( $e$ )

*A propensity score is a conditional probability of being assigned (or selected) to a treatment group <sup>4</sup>*

$$e_i = \Pr(Z_i = 1 | \mathbf{X}_i)$$

Treatment Group  
(e.g., Medication)

Baseline covariates



# Propensity Score Analysis Methods

Four methods of using propensity scores <sup>5</sup>

1. Propensity score matching
2. Stratification on the propensity score
3. Inverse probability of treatment weighting (IPTW) using the propensity score
4. Covariate adjustment using the propensity score



# Inverse Probability of Treatment Weighting (IPTW)

- ✓ Survival outcomes
- ✓ More complex study designs and research questions (e.g., time-varying confounders)
- ✓ No loss of sample (like matching and stratification)





# Types of Treatment Effect

- Average Treatment Effect (ATE)
  - Treatment effect for the *overall target population* in the study (treated and untreated subjects together)
- Average Treatment Effect among the Treated (ATT)
  - Treatment effect for the *treated* subjects only



# Inverse Probability of Treatment Weighting (IPTW)

- Estimated propensity scores were inverted to create IPTWs

$$w_{ate} = \frac{Z}{e} + \frac{1 - Z}{1 - e}$$

- Very large weights can cause instability: therefore stabilize weights by multiplying the IPTW by the marginal probability of receiving the actual treatment received

$$w_{ate,stab} = \Pr(Z = 1) \frac{Z}{e} + \Pr(Z = 0) \frac{1 - Z}{1 - e}$$

- Trim weights to 5<sup>th</sup> and 95<sup>th</sup> percentile



# Steps to Propensity Scoring

Steps	Method
1. Create weights on probability of being in medication treatment group based on variables from prior knowledge	<ul style="list-style-type: none"><li>• Logistic regression with logit link</li><li>• Invert to IPTWs</li><li>• Stabilize weights</li><li>• Truncate extreme weights</li></ul>
2. Assess weight distributions and overlap	<ul style="list-style-type: none"><li>• Histogram</li><li>• Box-plot</li></ul>
3. Assess balance of baseline covariates before and after weighting	<ul style="list-style-type: none"><li>• Standardized mean differences</li></ul>



# Outcome Analysis

Outcome	Analysis
1. Time to permanency	Cox proportional hazards regression model with IPTW
2. Placement stability	Poisson count regression with IPTW
3. Exit to permanency	Multinomial logistic regression with IPTW



# Outcome Analysis

## 1. Time to Permanent Exit

Weighted Cox Proportional Hazards Model with time-varying variables

$$\log h_i(t) = \alpha(t) + \beta_1 x_{i1} + \beta_2 x_{i2}(t)$$



# Outcome Analysis

## 2. Placement Stability

Poisson Count Regression exposure (time) offset

$$\log(E(y)) = b_0 + b_1x + b_1x(t) + \log(t_{exposure})$$

where

*y = dependent variable (count)*

*E(y) = Expected count value*

*x = Independent variables*

*b<sub>0</sub>, b<sub>1</sub> are regression coefficients*

*t = time period observed (exposure)*

*Log(t) is the offset variable*



# Outcome Analysis

## 3. Exit type

Weighted multinomial logistic regression with time-varying covariates

For  $m=2, \dots, M$  (outcomes)

$$P(Y_i = m) = \frac{\exp(Z_{mi})}{1 + \sum_{h=2}^M \exp(Z_{hi})}$$

For reference category,

$$P(Y_i = 1) = \frac{1}{1 + \sum_{h=2}^M \exp(Z_{hi})}$$



# Literature Review:

## Predictors of Psychotropic Medication Use Among Foster Youth

### Significant

- Older <sup>1, 2, 3, 5, 6, a</sup>
- Physical abuse <sup>1, 2, 3</sup>
- White <sup>1, 2, 3, 4, 5, b</sup>
- Male <sup>1, 2, 3, 6</sup>
- Poor health <sup>1, 2, 3</sup>
- Group home/out-of-home placement <sup>1, 2, 3, 4, 5, b</sup>
- Externalizing behavior <sup>1, 2, 3, 4</sup>
- Internalizing behavior <sup>2, 3, c</sup>

### Non-Significant

- Abandonment <sup>1, 2, 3, 6</sup>
- Sexual <sup>1, 3, 6, d</sup>
- Neglect <sup>1, 2, 3, 6</sup>
- Hispanic/Other (Ref. White) <sup>1, 2, 3</sup>
- Pediatrician/psychiatrist ratio <sup>6</sup>
- Rurality <sup>1, 2, 3</sup>
- Time in placement or instability <sup>5</sup>





# Data Management

- Linked foster care administrative dataset with Medicaid claims dataset using unique id
- Inclusion Criteria: Children entered into the North Carolina foster care system between March 1, 2006 and June 30, 2012
- If < 7 days between spells, spells were combined
- First spell only
- Excluded very young children (< 5 years of age)
- Excluded children with severe, psychotic disorders



# Measures

- Psychotropic Medication\*
- Gender (Male/Female)
- Race/Ethnicity
  - White (non-Hispanic)
  - Black (non-Hispanic)
  - Hispanic
  - Other/Mixed
- Age\* (0-4, 5-9, 10-14, 15-19)
- Abuse History
  - Physical abuse
  - Sexual Abuse
  - Neglect
  - Other
- Placement Type\*
  - Foster care
  - Therapeutic foster care
  - Kinship care
  - Residential care
  - Other
- Entry cohort
- Physical Disability
- Parent substance abuse
- Single parent household
- Rurality
- Diagnosis\*
- Number of Months in Care \*



# Measures

## Psychotropic Medication

1. Antidepressants
2. Antipsychotics
3. Moodstabilizers
4. Anxiolytic
5. Stimulants
6. Alpha-adrenergic agonist (AAA)




# Measures

## Diagnosis

1. Schizophrenia and other psychoses
2. Pervasive developmental disorders and mental retardation (PDD-MR)
3. Bipolar disorder
4. Disruptive disorders
5. Attention-deficit hyperactivity disorder (ADHD)
6. Depression disorders
7. Anxiety disorders
8. Adjustment disorder
9. Communication or learning disorders
10. Any other psychiatric diagnosis



# IPTW Distribution



# Balance Assessment

	Unmedicated (n=10,250 <sup>a</sup> )	Medicated (n=4,529 <sup>b</sup> )	Standardized Difference	
			Original Sample	Weighted Sample
<i>Gender</i>				
Male (ref. Female)	4,670 (45.6%)	2,521 (55.7%)	0.20	0.04
<i>Race</i>				
White	4,765 (46.5%)	2,512 (55.5%)	0.18	0.02
Black	3,770 (36.8%)	1,451 (32.0%)	0.10	0.00
Hispanic	928 (9.1%)	251 (5.5%)	0.15	0.04
Other	787 (7.7%)	315 (7.0%)	0.03	0.01
<i>Age at Entry</i>				
5 to 9 years	4,416 (43.1%)	1,650 (36.4%)	0.14	0.03
10 to 14 years	3,447 (33.6%)	1,706 (37.7%)	0.08	0.01
15 to 19 years	2,387 (23.3%)	1,173 (25.9%)	0.06	0.03
<i>Physical Disability</i>	43 (0.4%)	45 (1.0%)	0.06	0.01
<i>Parent</i>				
Substance abuse	2,893 (28.2%)	1,244 (27.5%)	0.02	0.01
Single parent	6,117 (59.7%)	2,694 (59.5%)	0.00	0.01
<i>Placement</i>				
Foster care	3,668 (35.8%)	1,637 (36.1%)	0.01	0.01
Therapeutic foster care	353 (3.4%)	366 (8.1%)	0.17	0.03
Group care	1,054 (10.3%)	748 (16.5%)	0.17	0.04
Kinship care	3,388 (33.1%)	1,068 (23.6%)	0.22	0.05
Other	1,787 (17.4%)	710 (15.7%)	0.05	0.01



# Balance Assessment

	Unmedicated (n=10,250 <sup>a</sup> )	Medicated (n=4,529 <sup>b</sup> )	Standardized Difference	
			Original Sample	Weighted Sample
<i>Abuse History</i>				
Physical abuse	783 (7.6)	377 (8.3%)	0.02	0.00
Sexual abuse	595 (5.8%)	277 (6.1%)	0.01	0.00
Neglect	7,838 (76.5%)	3,320 (73.3%)	0.07	0.02
Other	2,111 (20.6%)	1,063 (23.5%)	0.07	0.02
<i>Diagnosis</i>				
Disruptive disorder	1774 (17.3%)	2,418 (53.4%)	0.72*	0.04
ADHD	683 (6.7%)	1,100 (24.3%)	0.41*	0.08
ADHD	240 (2.3%)	790 (17.4%)	0.40*	0.20
Depressive disorders	138 (1.3%)	174 (3.8%)	0.13	0.00
Anxiety disorders	137 (1.3%)	100 (2.2%)	0.06	0.08
Adjustment disorder	305 (3.0%)	113 (2.5%)	0.03	0.28*
Other mental disorders	8,476 (82.7%)	141 (3.1%)	0.03	0.20
<i>Entry cohort (median)</i>	2008	2008	0.05	0.04
<i>Rurality</i>				
Urban (ref. Rural)	7,373 (71.9%)	3,335 (73.6%)	0.04	0.01

\*Standardized effect sizes in absolute values greater than 0.25

<sup>a</sup> 69.4% of total sample

<sup>b</sup> 30.6% of total sample

*Note.* ADHD = Attention deficit and hyperactivity disorder.

The weighted sample was constructed on the standardized inverse-probability of the treatment weighted (IPTW)

# Descriptive Data (Raw)



Outcome	Medicated (n=4,529)	Non-Medicated (n=10,2507)
<i>Length of Time in Care</i>		
Mean ( <i>SE</i> ; in months)	8.6 (0.17)	9.7 (0.12)
<i>Placement Stability</i>		
Average number of placements ( <i>SD</i> )	4.8 (5.2)	2.8 (3.6)
<i>Exit Type</i>		
Reunification	1,650 (36.4%)	4,178 (40.8%)
Adoption	692 (15.3%)	1,344 (13.1%)
Guardianship	1,126 (24.9%)	3,072 (30.0%)
No Permanency	1,061 (23.4%)	1,656 (16.2%)





# Outcome 1: Length of Time

## Survival Analysis



Bandwidth=3



# Outcome 1: Length of Time

## Cox Regression

Variable	Hazard Ratio (95% CI)	p value
<i>Medication</i>	0.40 (0.37-0.41)	< .0001
<i>Gender</i>		
Male (ref. Female)	0.99 (0.96-1.04)	NS
<i>Average age</i>	1.01 (1.01-1.02)	< .001
<i>Race</i>		
Black (ref. White)	1.11 (1.06-1.16)	< .0001
Hispanic (ref. White)	0.99 (0.92-1.07)	NS
Other (ref. White)	1.13 (1.04-1.22)	< .01
<i>MH diagnosis</i>		
Disruptive disorder	0.93 (0.87-0.98)	<.05
ADHD	0.94 (0.88-1.00)	NS
Depressive disorders	1.00 (0.90-1.10)	NS
Anxiety disorders	0.93 (0.83-1.03)	NS
Adjustment disorder	1.03 (0.94-1.14)	NS
Other mental disorders	0.88 (0.78-0.98)	<.05
<i>Physical disability</i>	1.01 (0.77-1.31)	NS
<i>Placement</i>		
Foster care	1.95 (1.82-2.08)	< .0001
Therapeutic foster care	1.82 (1.69-1.96)	< .0001
Kinship care	0.97 (0.90-1.04)	NS
Group home	1.45 (1.34-1.57)	< .0001
Other	-	-



# Outcome 1: Length of Time

## Cox Regression

Variable	Hazard Ratio (95% CI)		<i>p</i> value		
<i>Abuse</i>					
Physical	1.11 (1.04-1.19)		< .01		
Sex	1.20 (1.10-1.30)		< .0001		
Neglect	1.08 (0.96-1.22)		NS		
Other	1.09 (0.96-1.23)		NS		
<i>Parental characteristics</i>					
Substance abuse	0.98 (0.94-1.03)		NS		
Single parent	1.05 (1.01-1.09)		<.05		
<i>Entry cohort</i>	2.03 (2.00-2.06)		< .0001		
<i>Metropolitan</i>	0.99 (0.95-1.04)		NS		
<i>Number of placement changes</i>	0.51 (0.50-0.52)		< .0001		
Event and censored values:					
Events: 12,049					
Censored: 40,083					
Total: 52,132					
% Censored: 76.89					
	Without covariates	With covariates	Model chi-square	<i>df</i>	<i>p</i>
<i>-2 log L</i>	167,004.03	149,710.00	17,294.05	26	<.0001

*Note.* ADHD = Attention-deficit hyperactivity disorder; CI = Confidence interval; NS = Non-significant; ref. = Reference.



# Outcome 2: Placement Stability

Characteristic	B	Std. Error	Wald 95% CI		Incidence Rate Ratio
			Lower	Higher	
<i>Medication</i>	-0.19***	0.02	-0.23	-0.15	0.83
<i>Male</i>					
Male (ref. Female)	0.02	0.02	-0.02	0.06	1.02
<i>Age of Entry</i>	0.03***	0.00	0.02	0.03	1.03
<i>Race</i>					
Black (ref. White)	-0.03	0.02	-0.07	0.02	0.97
Hispanic (ref. White)	-0.10**	0.04	-0.17	-0.03	0.90
Other (ref. White)	0.01	0.04	-0.06	0.09	1.01
<i>MH diagnosis</i>	0.22***	0.02	0.18	0.26	1.25
<i>Physical disability</i>	-0.04	0.11	-0.26	0.18	0.96
<i>Placement</i>					
Foster care	0.14***	0.02	0.10	0.19	1.15
Therapeutic FC	0.29***	0.03	0.24	0.35	1.34
Kinship care	0.01	0.02	-0.04	0.05	1.01
Group home	0.27***	0.03	0.22	0.32	1.31
Other					
<i>Abuse</i>					
Physical	0.02	0.04	-0.05	0.09	1.02
Sex	-0.02	0.04	-0.10	0.06	0.98
Neglect	0.01	0.06	-0.11	0.12	1.01
Other	0.05	0.06	-0.07	0.17	1.05
<i>Parents</i>					
Substance abuse	-0.07***	0.02	-0.12	-0.03	0.93
Single parent	0.02	0.02	-0.02	0.06	1.02
<i>Entry Cohort</i>	0.06***	0.01	0.05	0.07	1.06
<i>Metro</i>	-0.01	0.02	-0.06	0.03	0.99

Note. FC = Foster care; MH = Mental health; ref. = Reference.

\*  $p \leq .05$ ; \*\*  $p \leq .01$ ; \*\*\*  $p \leq .001$

# Outcome 3: Exit Type

Characteristic	Reunification v. No permanency		Guardianship v. No permanency		Adoption v. No permanency	
	OR (95% CI)		OR (95% CI)		OR (95% CI)	
Medication	0.50 (0.43-0.58)	***	0.59 (0.50-0.70)	***	1.03 (0.85-1.25)	
Male						
Male (ref. Female)	1.06 (0.88-1.28)		1.08 (0.88-1.32)		0.85 (0.66-1.09)	
Age of entry	0.74 (0.72-0.76)	***	0.73 (0.71-0.76)	***	0.58 (0.56-0.61)	***
Race						
Black (ref. White)	0.65 (0.53-0.79)	***	0.75 (0.60-0.93)	*	0.72 (0.55-0.94)	*
Hispanic (ref. White)	0.62 (0.43-0.88)	**	0.75 (0.49-1.14)		0.75 (0.49-1.15)	
Other (ref. White)	0.84 (0.57-1.24)		0.92 (0.59-1.41)		1.02 (0.62-1.68)	
MH diagnosis						
Disruptive disorder	0.78 (0.68-0.90)	***	0.69 (0.59-0.81)	***	0.74 (0.60-0.91)	**
ADHD	0.88 (0.70-1.10)		0.97 (0.77-1.22)		1.17 (0.90-1.53)	
Depressive disorder	0.84 (0.65-1.08)		0.96 (0.73-1.28)		1.08 (0.69-1.70)	
Anxiety	1.07 (0.79-1.43)		0.81 (0.58-1.13)		1.70 (1.23-2.34)	**
Adjustment	0.87 (0.71-1.07)		0.97 (0.78-1.20)		1.13 (0.89-1.45)	
Other	1.05 (0.81-1.35)		1.07 (0.81-1.42)		1.09 (0.77-1.55)	
Physical disability	0.36 (0.15-0.83)	*	0.30 (0.12-0.77)	*	0.27 (0.08-0.87)	*
Placement						
Foster care (ref. Other)	0.42 (0.36-0.50)	***	0.57 (0.47-0.69)	***	2.03 (1.55-2.64)	***
Therapeutic FC (ref. Other)	0.26 (0.21-0.32)	***	0.38 (0.29-0.50)	***	1.70 (1.23-2.34)	**
Kinship care (ref. Other)	0.64 (0.53-0.78)	***	2.39 (1.94-2.94)	***	3.56 (2.65-4.78)	***
Group home (ref. Other)	0.57 (0.49-0.66)	***	0.67 (0.55-0.81)	***	1.57 (1.14-2.18)	**

# Outcome 3: Exit Type

Characteristic	Reunification v. No permanency	Guardianship v. No permanency	Adoption v. No permanency
	OR (95% CI)	OR (95% CI)	OR (95% CI)
Abuse			
Physical	1.07 (0.77-1.50)	0.95 (0.65-1.39)	1.05 (0.69-1.62)
Sex	0.74 (0.52-1.05)	0.69 (0.47-1.00)	0.78 (0.49-1.23)
Neglect	0.87 (0.54-1.39)	0.64 (0.39-1.06)	1.34 (0.65-2.76)
Other	0.77 (0.46-1.27)	0.51 (0.30-0.88)	0.81 (0.37-1.77)
Parents			
Substance abuse	0.89 (0.71-1.12)	1.20 (0.94-1.53)	1.18 (0.89-1.56)
Single parent	0.81 (0.67-0.97)	1.08 (0.88-1.33)	0.93 (0.73-1.19)
Entry Cohort	1.07 (1.02-1.12)	1.06 (1.01-1.12)	1.09 (1.02-1.16)
Number of months in care	0.95 (0.94-0.96)	0.96 (0.95-0.97)	1.05 (1.04-1.06)
Metropolitan (ref. Rural)	0.89 (0.72-1.09)	0.72 (0.57-0.91)	1.22 (0.91-1.62)
Placement changes	0.94 (0.90-0.97)	0.96 (0.92-1.00)	0.71 (0.66-0.76)

Note. ADHD = Attention-deficit hyperactivity disorder; FC = Foster care; MH = Mental health; ref. = Reference.

\*  $p \leq .05$ ; \*\*  $p \leq .01$ ; \*\*\*  $p \leq .001$

# Discussion



# Major Findings

1. Medicated children stayed in care longer
  - Medication is not a quick-fix solution
  - Possible delays when medicated:
    - Court order mandating mental health treatment goals met
    - Delays in establishing appropriate specialist<sup>6, 7</sup>





# Major Findings

## 2. Placements of medicated children were more stable

- Time exposure may be suppressing placement instability rates as medicated children tend to be in care longer
- Medicating may address problem behavior that is a risk factor of placement disruptions<sup>8</sup>
- Placement disruptions associated with increased mental health need and poor social emotional outcomes<sup>9, 10, 11, 12</sup>
- More studies on disruptive behavior on placement stability



# Major Findings

3. Medicated children less likely to achieve permanency
  - Medication treatment modality only addresses the child, not their parents
  - Meeting needs of parents a greater challenge

13



# Clinical Relevance

- Medication may help children exit foster care faster in the beginning months by stabilizing them although does not have this effect in later months
- Medicating children may help improve placement stability
- Provide a holistic approach to treatment



# Policy Relevance

- Ensure that family services are part of the treatment plan in addition to medication to help improve exits to permanency
- Facilitate cross-system data sharing



# Limitations and Strengths

## Strengths

- Large sample size
- Longitudinal
- Human, safe, and non-intrusive
- Propensity scoring with IPTW
- Time-varying covariates
- Causal analysis

## Limitations

- Unobserved confounders
- No behavioral covariates
- Abuse severity unknown
- The tenuous overlap of propensity scores may lead to imprecise estimates and sensitive to misspecification
- Some samples needed to be deleted (need larger sample size)



# Further Considerations and Future Work

- Incorporate time-varying nature of treatment (e.g., marginal structural modeling)
- Other outcome measures (e.g., health, education, juvenile justice, etc.)



# Conclusions

- Medicated children less likely to exit to permanency
- Medicated children in care longer
- Medicated children more stable
- IPTW is promising and viable technique for causal analysis involving observational datasets
- Potential to use for other outcomes to determine whether care and services help children lead healthy and productive lives



# Overall Limitations Administrative Data

## Disadvantages

- Variables limited to what is collected
- Data quality management

## Advantages

- Wealth of data
- Big sample size
- Longitudinal
- Unobtrusive





# Overall Limitations

## Propensity Score Analysis

### Disadvantages

- Assumes there are no unmeasured confounders that influenced treatment assignment
- Requires very large samples

### Advantages

- Cheaper and quicker than RCTs
- Study treatments that would be infeasible or unethical to randomize
- Useful when adjusting for a large number of risk factors



# Summary

- A substantial percentage of children in foster care are treated with psychotropic medication
- Existing literature vary in quality and findings
- Few studies go beyond exploratory research
- Advanced statistics can be applied to large, administrative datasets to mimic randomized control trials and help make causal inferences
- Cross-systems data provide even more rich information on experiences and outcomes of children in foster care



# References: Introduction

1. Child Welfare Information Gateway. (2013). *Foster Care Statistics 2011*. Washington, DC. Retrieved from <https://www.childwelfare.gov/pubs/factsheets/foster.pdf>
2. National Institute on Mental Health [NIMH]. (2009). *Treatment of children with mental illness*. (NIH Publication No. 09-4702). Retrieved March 20, 2012, from <http://www.nimh.nih.gov/health/publications/treatment-of-children-with-mental-illness-fact-sheet/nimh-treatment-children-mental-illness-faq.pdf>
3. Burns, B. J., Phillips, S. D., Wagner, H. R., Barth, R. P., Kolko, D. J., Campbell, Y., & Landsverk, J. (2004). Mental health need and access to mental health services by youths involved with child welfare: a national survey. *Journal of the American Academy of Child Adolescent Psychiatry*, 43(8), 960-970. doi:10.1097/01.chi.0000127590.95585.65
4. DosReis, S., Zito, J. M., Safer, D. J., & Soeken, K. L. (2001). Mental health services for youths in foster care and disabled youths. *American Journal of Public Health*, 91(7), 1094-1099. doi:10.2105/AJPH.91.7.1094
5. Leslie, L. K., Hurlburt, M. S., Landsverk, J., Barth, R., & Slymen, D. J. (2004). Outpatient mental health services for children in foster care: A national perspective. *Child Abuse & Neglect*, 28(6), 697-712.
6. Government Accountability Office [GAO]. (2011). *Foster children: HHS guidance could help states improve oversight of psychotropic prescriptions*. (NIH Publication No. GAO-09-26). Washington, DC: Office USGA.
7. National Institute of Mental Health. (2016, October). *Mental health medications*. Retrieved from <https://www.nimh.nih.gov/health/topics/mental-health-medications/index.shtml>
8. Leslie, L. K., Raghavan, R., Zhang, J., & Aarons, G. A. (2010). Rates of psychotropic medication use over time among youth in child welfare/child protective services. *Journal of Child Adolescent Psychopharmacology*, 20(2), 135-143. doi:10.1089=cap.2009.0065
9. Maglione, M., Maher, A. R., Hu, J., Wang, Z., Shnman, R., Shekelle, P. G., ... Perry, T. (2011). *Off-Label Use of Atypical Antipsychotics : An Update*. Rockville, MD. Retrieved from [www.effectivehealthcare.ahrq.gov/reports/final.cfm](http://www.effectivehealthcare.ahrq.gov/reports/final.cfm)
10. National Institute of Mental Health. (2016, October). *Mental health medications*. Retrieved from <https://www.nimh.nih.gov/health/topics/mental-health-medications/index.shtml>



# References: Literature Review

1. Raghavan, R., Brown, D. S., Thompson, H., Ettner, S. L., Clements, L. M., & Key, W. (2012). Medicaid expenditures on psychotropic medications for children in the child welfare system. *Journal of Child & Adolescent Psychopharmacology*, 22(3), 182–189. doi:10.1089/cap.2011.0135
2. Raghavan, R., Brown, D. S., Allaire, B. T., Garfield, L. D., & Ross, R. E. (2014a). Medicaid expenditures on psychotropic medications for maltreated children: A study of 36 states. *Psychiatric Services*, 65(12), 1445–1451. doi:10.1176/appi.ps.201400028
3. Raghavan, R., Brown, D. S., Allaire, B. T., Garfield, L. D., Ross, R. E., & Snowden, L. R. (2014b). Racial/ethnic differences in Medicaid expenditures on psychotropic medications among maltreated children. *Child Abuse & Neglect*, 38(6), 1002–1010. doi:10.1016/j.chiabu.2014.02.013
4. Breland-Noble, A. M., Elbogen, E. B., Farmer, E. M. Z., Dubs, M. S., Wagner, H. R., & Burns, B. J. (2004). Use of psychotropic medications by youths in therapeutic foster care and group homes. *Psychiatric Services*, 55(6), 706–708. doi:10.1176/appi.ps.55.6.706
5. Zima, B. T., Bussing, R., Crecelius, G. M., Kaufman, A., & Belin, T. R. (1999). Psychotropic medication use among children in foster care: Relationship to severe psychiatric disorders. *American Journal of Public Health*, 89(11), 1732–1735.
6. Leslie, L. K., Raghavan, R., Hurley, M., Zhang, J., Landsverk, J., & Aarons, G. A. (2011). Investigating geographic variation in use of psychotropic medications among youth in child welfare. *Child Abuse & Neglect*, 35(5), 333–342. doi:10.1016/j.chiabu.2011.01.012



# References: Methods & Discussion

1. Rubin, D. B. (1978). Bayesian inference for causal effects: The role of randomization. *The Annals of Statistics*, 6(1), 34–58.
2. Shadish, W. R., Cook, T. D., & Campbell, D. T. (2002). *Experimental and quasi-experimental designs for generalized causal inference*. Boston, MA: Houghton, Mifflin and Company.
3. Thoemmes, F., & Kim, E. S. (2011). A systematic review of propensity score methods in the social sciences. *Multivariate Behavioral Research*, 46(1), 90-118. doi:10.1080/00273171.2011.540475
4. Rosenbaum, P. R., & Rubin, D. B. (1983). The central role of the propensity score in observation studies for causal effects, *Biometrika*, 70(1), 41-55. doi:10.1093/biomet/70.1.41
5. Austin, P. C. (2014). The use of propensity score methods with survival or time-to-event outcomes: Reporting measures of effect similar to those used in randomized experiments. *Statistics in Medicine*, 33, 1242–1258. doi:10.1002/sim.5984.
6. O'Brien, D., Harvey, K., Howse, J., Reardon, T., & Creswell, C. (2016). Barriers to managing child and adolescent mental health problems: A systematic review of primary care practitioners' perceptions. *British Journal of General Practice*, 66(651), e693–e707. doi:10.3399/bjgp16X687061
7. Pfefferle, S. G. (2007). Pediatrician perspectives on children's access to mental health services: Consequences and potential solutions. *Administration and Policy in Mental Health and Mental Health Services Research*, 34(5), 425–434. doi:10.1007/s10488-007-0122-2
8. Fisher, P. A., Stoolmiller, M., Mannering, A. M., Takahashi, A., & Chamberlain, P. (2011). Foster placement disruptions associated with problem behavior: Mitigating a threshold effect. *Journal of Consulting and Clinical Psychology*, 79(4), 481–487. doi:10.1037/a0024313
9. James, S., Landsverk, J., & Slymen, D. J. (2004). Placement movement in out-of-home care: Patterns and predictors. *Children and Youth Services Review*, 26(2), 185–206. doi:10.1016/j.childyouth.2004.01.008
10. Lewis, E. E., Dozier, M., Ackerman, J., & Sepulveda-Kozakowski, S. (2007). The effect of placement instability on adopted children's inhibitory control abilities and oppositional behavior. *Developmental psychology*, 43(6), 1415–1427. doi: 10.1037/0012-1649.43.6.1415
11. Rubin, D. M., Alessandrini, E. A., Feudtner, C., Mandell, D. S., Localio, A. R., & Hadley, T. (2004). Placement stability and mental health costs for children in foster care. *Pediatrics*, 113(5), 1336–1341.
12. Ryan, J. P., & Test, M. F. (2005). Child maltreatment and juvenile delinquency: Investigating the role of placement and placement instability. *Children and Youth Services Review*, 27(3), 227–249. doi:10.1016/j.childyouth.2004.05.007
13. Marcenko, M. O., Newby, M., Lee, J., Courtney, M., & Brennan, K. (2009). Evaluation of Washington's solution based casework practice model: Baseline parent survey. Seattle, WA: Partners of Our Children, University of Washington, School of Social Work.

